OKOMERA

About the company

Okomera specializes in automated 3D organoid screening technology that accelerates access to improved, precision-based cancer therapies. Their goal is to advance personalized medicine by providing healthcare actors with powerful tools to analyze how tumors respond to various therapies.

Okomera integrates standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity.

About the solution

They have developed a miniaturized 3D assay to help clinical decision. Using a biopsy of the tumor, Okomera’s cell culture technology includes: a fluidic machine, reagents, and a software analysis designed to estimate and identify the best drug treatment for each cancer patient.

Website

Key information

– Therapeutic areas: Oncology, Assays on chip, Drug discovery

– Based in: Paris (FRANCE)
Berkeley (US)

– Employees: 11 – 50

– Created in: 2020

SATT AxLR

About the company

SATT AxLR is a TTO based in south of France with a focus on innovative health projects from academic teams. SATT AxLR is funding early stages to allow project reaching a stage for technical transfer or company creation.

About the solution

SATT AxLR provide advice, contacts, funding to academic researchers (Universities, Hospitals, Public Instittutes,..) and generate intellectual property that is available for licensing.

Website

Key information

– Therapeutic areas: Oncology, Immunology, CNS, Cardiology, Rare diseases, Obesity, Cell therapy, Medical Device

– Based in: Montpellier (FRANCE)

– Employees: 11 – 50

– Created in: 2012